Metformin pretreatment reduces effect to dacarbazine and suppresses melanoma cell resistance |
| |
Authors: | Larissa J. Sanches,Poliana C. Marinello,Walison A. da Silva Brito,Nat lia M. D. Lopes,Rodrigo C. Luiz,Rubens Cecchini,Alessandra L. Cecchini |
| |
Affiliation: | Larissa J. Sanches,Poliana C. Marinello,Walison A. da Silva Brito,Natália M. D. Lopes,Rodrigo C. Luiz,Rubens Cecchini,Alessandra L. Cecchini |
| |
Abstract: | Oxidative stress role on metformin process of dacarbazine (DTIC) inducing resistance of B16F10 melanoma murine cells are investigated. To induce resistance to DTIC, murine melanoma cells were exposed to increasing concentrations of dacarabazine (DTIC-res group). Metformin was administered before and during the induction of resistance to DTIC (MET-DTIC). The oxidative stress parameters of the DTIC-res group showed increased levels of malondialdehyde (MDA), thiol, and reduced nuclear p53, 8-hydroxy-2?-deoxyguanosine (8-OH-DG), nuclear factor kappa B (NF-?B), and Nrf2. In presence of metformin in the resistant induction process to DTIC, (MET-DTIC) cells had increased antioxidant thiols, MDA, nuclear p53, 8-OH-DG, Nrf2, and reducing NF-?B, weakening the DTIC-resistant phenotype. The exclusive administration of metformin (MET group) also induced the cellular resistance to DTIC. The MET group presented high levels of total thiols, MDA, and reduced percentage of nuclear p53. It also presented reduced nuclear 8-OH-DG, NF-?B, and Nrf2 when compared with the control. Oxidative stress and the studied biomarkers seem to be part of the alterations evidenced in DTIC-resistant B16F10 cells. In addition, metformin administration is able to play a dual role according to the experimental protocol, preventing or inducing a DTIC-resistant phenotype. These findings should help future research with the aim of investigating DTIC resistance in melanoma. |
| |
Keywords: | adjuvant therapy B16F10 chemoresistance Nrf2 p53 |
|
|